Is earnings in the PM or AH tomorrow? Thanks!
Hey profit, you seem to know a lot about how the market works. What do you mean by:
1) "agree 60% short position in yesterdays volume"
2)" MM's getting ready"
What???? I I had six dislikes??? Why??...why??.....I am crying......why?????
Only silly traders will sell this for less than $2/share. Upgrades are inevitable and the rally to $3+ is about to start.
LOL....you got 3 dislikes in 30 seconds.
Great call though, you were pumping GIG at $1.68 when AMD and GIG were at the same price. It looks like they will be going in opposite directions from this point forward.
Great call......you've been pumping this puppy at $1.68 yesterday. Solid company....the real deal....does not need pumping
I agree...excellent execution on all fronts. I see $2+ in a few days ....after that GIG will never look back because 2016 is looking like a significant improvement over record 2015 with new products like small cells and others
Not only the numbers were in the record area .......this CC was also the longest-lasting CC for GIG with over 1 hour of excellence.....
GigOpttix has 60c/share cash and zero debt....Analysts have a $3/share target which will likely be raised after today's earnings report.
Preannouncement: (June 29, 2015)
- Record quarterly revenues
- Record non-GAAP profitability
- First GAAP-profitable quarter ever
- Raised guidance for FY 2015 - This means that 3Q & 4Q 2015 will also be GAAP profitable
- Growing at over 20%/year CAGR
- fastest growing company in the semi industry
Other excerpts from preannouncement:
Continued robust demand in the firm's High Speed Communications product line - primarily for its QSFP+ drivers and trans-impedance amplifiers (TIAs) for data-center active optical cables (AOC) and transceivers, and the linear-coherent 100Gbps and 200Gbps drivers for use in long-haul and metro telecom applications, as well as new business opportunities in the Industrial product line – has resulted in the higher than initially forecasted revenue.
Based on these preliminary revenue results for second-quarter 2015, along with continued healthy margin performance and tight expense controls, GigOptix also believes that it will achieve positive GAAP net income and record non-GAAP profitability.
In addition, as a result of the better than initially forecasted revenue performance for first-half 2015 (up 22% year-on-year) and the current continuous strong growth outlook for both the third quarter and the remainder of 2015, GigOptix has raised its revenue forecast for full-year 2015 by 4% (from the previously announced guidance midpoint of $37.5m) to at least $39m (up 19% on $32.9m for 2014).
GIG recently raised guidance for 2Q 2015 and FY 2015. The company will start reporting GAAP profitability going forward on over 20% CAGR yearly growth rate and over 60% gross margins. The company is also bidding to acquire larger company GSIT. The combined company would generate over $100 million in revenues and be highly GAAP profitable........you must do your DD now because this is a high-reward low-risk opportunity .....
GIG even without cash-rich GSIT has over 60c/share cash with no debt....the market is only valuing the stock at $1/share over cash!!!
Analysts covering the stock has a $3/share target which will likely be upgraded after tomorrow's earnings release
Seeking alpha has a nice article on GIG to help you begin your DD but I can't post the link here. Search for Seekingalpha GIG and you'll find it .....also go to GIG's news about the preannouncement that lifted the stock to $1.95 when that's happened a few weeks ago. GIG is still under the radar but it will not anymore after the July 27 AH earnings release.
MMs have been manipulating the stock in an effort to accumulate shares.....Your best opportunity to get in on a ground level is Monday morning......The price will rally as earnings AH approach....after that it's blue skies baby!!!!
Great pick....Thank you!
Easy 50% gain here my friends. Company growing profitably at a 20%/year CAGR and has 60c/share cash and no debt. It will be $5+ in a couple of quarters
Lpath, Inc.(LTPN) the industry leader in bioactive lipid-targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab™. The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial upon investigational review board approvals and anticipates the first subject to be dosed within two months.
Lpathomab is an antibody targeting lysophosphatidic acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies have shown strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy. Other preclinical studies have also demonstrated the potential for Lpathomab as a treatment for traumatic brain injury, and preclinical studies for this indication are currently underway in conjunction with the U.S. Department of Defense at Walter Reed Army Institute of Research as well as at academic institutions.
In addition to advancing Lpathomab into the clinic, Lpath intends to generate in vivo data in select programs, including Altepan™ and other earlier stage preclinical candidates, in order to identify the company's next clinical candidates and indications to pursue. Simultaneously, Lpath will actively explore partnering, licensing and monetization options for its pipeline assets. Lpath's proprietary discovery platform continues to be effective at creating bioactive lipid-targeted monoclonal antibody therapeutics. By reprioritizing its research and development programs, Lpath will continue to advance its discove
Remember, knowledge is power. Load up at these prices and hold. The longer you will hold the better off you will be.
Next set of interim results due out in a couple of months. Phases 1 and 2 were successful
The Data Safety Monitoring Board recommended on April 27, 2015 that Phase 3 should proceed as planned:
April 27, 2015
Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer
DSMB's recommendation follows 1rst interim analysis
Québec City, Canada, April 27, 2015 – Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that the independent Data Safety Monitoring Board (“DSMB”) for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, has completed a pre specified first interim futility analysis. The DSMB has recommended that the Phase 3 study continue as planned.
David Dodd, Chairman and CEO of Aeterna Zentaris, commented, “We are very pleased with this positive recommendation from the DSMB on our ZoptEC Phase 3 trial in endometrial cancer, and I would like to thank everyone involved in this project for their unwavering dedication. With approximately 90 % of patients enrolled at this time, we are well on our way of completing patient recruitment ahead of the anticipated timeline. We believe that zoptarelin doxorubicin has the potential to become the first FDA approved medical therapy for advanced, recurrent endometrial cancer This could result in its rapid adoption as a novel core therapy for patient treatment & management, and therefore, could represent a significant market opportunity for the Company. Moving forward, we are continuing to develop our commercialization plans regarding zoptarelin doxorubicin in this indication, including establishing additional partnerships in territories that won't be pursued by Aeterna Zentaris. In addition, contingent on the success of the ZoptEC program, we have additional areas of interest for further therapeutic development, including ovarian, prostate and triple negative breast cancer. Our commitment is to ensure t
Ypu will see soon that the author was 100% right . I see a 100% gain after earnings